Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | October 07, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2036-10-07 | Direct | 127,061 |
Reported balance
After 2026-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-07 · Grant · Acquired 127,061 · Balance 127,061 F1: The option will vest in 36 equal installments on each monthly anniversary of the date of grant such that the shares subject to the option are fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 36 equal installments on each monthly anniversary of the date of grant such that the shares subject to the option are fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 8, 2026 20:49 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 127,061 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001193125-26-418022 · ownership.xml · derivative · entry 1 Zhang Zhongwei · CIK 0002122235 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,061 Underlying: Common Stock · 127,061 shares Expires 2036-10-07 F1 · derivative.exercise_date: The option will vest in 36 equal installments on each monthly anniversary of the date of grant such that the shares subject to the option are fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.